In accordance with evidence indicating that glioblastoma and leukemic CSCs present an enhanced susceptibility to LMP-inducing agents [19,20], well-established LMP-inducers mefloquine and siramesine also affected PDAC2 CSC viability with varying potencies (Figure 6A). This evidence concerns the gene PDLIM7 and glioblastoma.